Animal models for hepatocellular carcinoma arising from alcoholic and metabolic liver diseases

Abstract

Hepatocellular carcinoma (HCC) is a major and increasing cause of clinical and economic burden worldwide. Now that there are effective therapies to control or eradicate viral aetiologies, the landscape of HCC is changing with alcoholic and metabolic liver diseases becoming major catalysts. The pathogenesis of HCC is complex and incompletely understood, hampering improvements in therapy. Animal models are essential tools for advancing study on the cellular and molecular processes in HCC and for screening potential novel therapies. Many models of hepatocarcinogenesis have been established using various methods including genetic engineering, chemotoxic agents and dietary manipulation to direct implantation of tumour cells. However, none of these can accurately replicate all features found in human diseases. In this review, we provide an overview of different mouse models of HCC with a particular focus on cancer arising from alcoholic liver disease, non-alcoholic fatty liver disease and hereditary haemochromatosis. We also highlight their strengths and limitations and provide perspectives for future study.

Keywords

Hepatocellular carcinoma / animal models / mouse models / non-alcoholic fatty liver disease / alcohol / haemochromatosis

References

[1] El-Serag HB.Hepatocellular carcinoma..N Engl J Med2011;365:1118-27

[2] Wallace MC,Jeffrey GP.The evolving epidemiology of hepatocellular carcinoma: a global perspective..Expert Rev Gastroenterol Hepatol2015;9:765-79

[3] Wong MC,Goggins WB,Fang Y.International incidence and mortality trends of liver cancer: a global profile..Sci Rep2017;7:45846 PMCID:PMC5374459

[4] Bertuccio P,Carioli G,La Vecchia C.Global trends and predictions in hepatocellular carcinoma mortality..J Hepatol2017;67:302-9

[5] Rinella M.The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health..Hepatology2016;64:19-22

[6] Loomba R.The global NAFLD epidemic..Nat Rev Gastroenterol Hepatol2013;10:686-90

[7] Ertle J,Sowa JP,Herzer K.Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis..Int J Cancer2011;128:2436-43

[8] Dyson J,Chattopadyhay D,Graham J.Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team..J Hepatol2014;60:110-7

[9] Cho EJ,Jang ES,Lee JH.Relative etiological role of prior hepatitis B virus infection and nonalcoholic fatty liver disease in the development of non-B non-C hepatocellular carcinoma in a hepatitis B-endemic area..Digestion2011;84:17-22

[10] Okanoue T,Yasui K.Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan..J Gastroenterol Hepatol2011;26:153-62

[11] Ganne-Carrié N.Hepatocellular carcinoma in the setting of alcohol-related liver disease..J Hepatol2019;70:284-93

[12] Global Burden of Disease Liver Cancer CollaborationThe burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level results from the global burden of disease study 2015..JAMA Oncol2017;3:1683-91 PMCID:PMC5824275

[13] Deugnier Y.Iron and hepatocellular carcinoma..J Gastroenterol Hepatol2001;16:491-4

[14] Sorrentino P,Ferbo U,Bracigliano A.Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis..J Hepatol2009;50:351-7

[15] Thillai K,Sarker D.Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?.World J Gastrointest Oncol2016;8:173-85 PMCID:PMC4753168

[16] Nault JC.The end of almost 10 years of negative RCTs in advanced hepatocellular carcinoma..Lancet2017;389:4-6

[17] Llovet JM,Mazzaferro V,Gane E.Sorafenib in advanced hepatocellular carcinoma..N Engl J Med2008;359:378-90

[18] Forner A,Bruix J.Hepatocellullar carcinoma..Lancet2018;391:1301-14

[19] Newell P,Friedman SL,Llovet JM.Experimental models of hepatocellular carcinoma..J Hepatol2008;48:858-79 PMCID:PMC2990959

[20] Bruix J,Gores G,Mazzaferro V.Liver cancer: approaching a personalized care..J Hepatol2015;62:S144-56 PMCID:PMC4520430

[21] Brown ZJ,Greten TF.Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research..Nat Rev Gastroenterol Hepatol2018;15:536-54

[22] Lau JKC,Yu J.Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances..J Pathol2017;241:36-44 PMCID:PMC5215469

[23] Ba Q,Huang H,Ge A.Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies..Clin Cancer Res2011;17:7625-33

[24] Santos NP,Oliveira PA.Animal models as a tool in hepatocellular carcinoma research: a review..Tumour Biol2017;39:1-20

[25] Vogelstein B,Velculescu VE,Diaz Jr LA.Cancer genome landscapes..Science2013;339:1546-58 PMCID:PMC3749880

[26] Yan J,Schwabe RF.Animal models of HCC - when injury meets mutation..J Hepatol2018;68:193-4

[27] Liu Y,Zeng Z,Wang J.CRISPR/Cas9-mediated p53 and Pten dual mutation accelerates hepatocarcinogenesis in adult hepatitis B virus transgenic mice..Sci Rep2017;7:2796 PMCID:PMC5459841

[28] Horie Y,Kataoka E,Hamada K.Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas..J Clin Invest2004;113:1774-83 PMCID:PMC420505

[29] Katz SF,Obenauf AC,Kraus JM.Disruption of Trp53 in livers of mice induces formation of carcinomas with bilineal differentiation..Gastroenterology2012;142:1229-39.e3

[30] Santoni-Rugiu E,Thorgeirsson SS.Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha..Cancer Res1998;58:123-34

[31] Kent LN,Tsai SY,Srivastava A.Dosage-dependent copy number gains in E2f1 and E2f3 drive hepatocellular carcinoma..J Clin Invest2017;127:830-42 PMCID:PMC5330731

[32] Ruiz de Galarreta M,Molina-Sánchez P,Maier B.β-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma..Cancer Discov2019;9:1124-41 PMCID:PMC6677618

[33] Bakiri L.Mouse models for liver cancer..Mol Oncol2013;7:206-23 PMCID:PMC5528415

[34] Dow M,Tsui BY,Nakagawa H.Integrative genomic analysis of mouse and human hepatocellular carcinoma..Proc Natl Acad Sci U S A2018;115:E9879-88 PMCID:PMC6196518

[35] Fidler IJ.Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis..Cancer Metastasis Rev1986;5:29-49

[36] He S,Li C,Tang WG.PDXliver: a database of liver cancer patient derived xenograft mouse models..BMC Cancer2018;18:550 PMCID:PMC5944069

[37] Broutier L,Verstegen MM,Gavarró LM.Human primary liver cancer-derived organoid cultures for disease modeling and drug screening..Nat Med2017;23:1424-35 PMCID:PMC5722201

[38] Sun FX,Lui KD,Xue Q.Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues..Int J Cancer1996;66:239-43

[39] Calvisi DF,Gorden A,Conner EA.Ubiquitous activation of Ras and Jak/Stat pathways in human HCC..Gastroenterology2006;130:1117-28

[40] Lee JS,Mikaelyan A,Heo J.Application of comparative functional genomics to identify best-fit mouse models to study human cancer..Nat Genet2004;36:1306-11

[41] Inokuchi S,Miura K,Kodama Y.Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis..Proc Natl Acad Sci U S A2010;107:844-9 PMCID:PMC2818947

[42] Katzenellenbogen M,Pappo O,Olam D.Molecular mechanisms of liver carcinogenesis in the mdr2-knockout mice..Mol Cancer Res2007;5:1159-70

[43] Popov Y,Fickert P,Schuppan D.Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes..J Hepatol2005;43:1045-54

[44] Arvola A.Comparison between water and alcohol consumption in six animal species in free choice experiments..Nature1961;191:819-20

[45] Holmes RS,Algar EM,Rout UK.Biochemical and genetic studies on enzymes of alcohol metabolism: the mouse as a model organism for human studies..Alcohol Alcohol1986;21:41-56

[46] Bertola A.Rodent models of fatty liver diseases..Liver Res2018;2:3-13

[47] Friemel J,Unger K,Parrotta R.Characterization of HCC mouse models towards an etiology-oriented subtyping approach..Mol Cancer Res2019;17:1493-502

[48] Ambade A,Gyongyosi B,Szabo G.Adult mouse model of early hepatocellular carcinoma promoted by alcoholic liver disease..World J Gastroenterol2016;22:4091-108 PMCID:PMC4837428

[49] Rafacho BPM,Liu C,Ausman LM.Inhibition of diethylnitrosamine-initiated alcohol-promoted hepatic inflammation and precancerous lesions by flavonoid luteolin is associated with increased sirtuin 1 activity in mice..Hepatobiliary Surg Nutr2015;4:124-34 PMCID:PMC4405419

[50] Brandon-Warner E,Schrum LW.Chronic ethanol feeding accelerates hepatocellular carcinoma progression in a sex-dependent manner in a mouse model of hepatocarcinogenesis..Alcohol Clin Exp Res2012;36:641-53 PMCID:PMC3288433

[51] Naugler WE,Kim S,Kim K.Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production..Science2007;317:121-4

[52] De Minicis S,Francis H,Benedetti A.Liver carcinogenesis: rodent models of hepatocarcinoma and cholangiocarcinoma..Dig Liver Dis2013;45:450-9 PMCID:PMC3716909

[53] Xin B,Wang Y,Yin J.Combined use of alcohol in conventional chemical-induced mouse liver cancer model improves the simulation of clinical characteristics of human hepatocellular carcinoma..Oncol Lett2017;14:4722-8 PMCID:PMC5649534

[54] Liu K.Epidemiology and etiologic associations of non-alcoholic fatty liver disease and associated HCC..Adv Exp Med Biol2018;1061:3-18

[55] Wolf MJ,Piotrowitz K,Boege Y.Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes..Cancer Cell2014;26:549-64

[56] De Minicis S,Rychlicki C,Saccomanno S.HCC development is associated to peripheral insulin resistance in a mouse model of NASH..PLoS One2014;9:e97136 PMCID:PMC4031080

[57] Hill-Baskin AE,Buchner DA,DeSantis D.Diet-induced hepatocellular carcinoma in genetically predisposed mice..Hum Mol Genet2009;18:2975-88 PMCID:PMC2714725

[58] Kanuri G.In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD)..Int J Mol Sci2013;14:11963-80 PMCID:PMC3709766

[59] Asgharpour A,Pacana T,Vincent R.A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer..J Hepatol2016;65:579-88 PMCID:PMC5012902

[60] Tsuchida T,Fujiwara N,Allen B.A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer..J Hepatol2018;69:385-95 PMCID:PMC6054570

[61] Kishida N,Itano O,Kitago M.Development of a novel mouse model of hepatocellular carcinoma with nonalcoholic steatohepatitis using a high-fat, choline-deficient diet and intraperitoneal injection of diethylnitrosamine..BMC Gastroenterol2016;16:61 PMCID:PMC4906823

[62] Park EJ,Yu GY,Ali SR.Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression..Cell2010;140:197-208 PMCID:PMC2836922

[63] Liang JQ,Xu L,Li X.Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling..Nat Commun2018;9:4490 PMCID:PMC6203711

[64] Henderson JM,Chen J,Weninger W.Multiple liver insults synergize to accelerate experimental hepatocellular carcinoma..Sci Rep2018;8:10283 PMCID:PMC6035229

[65] Castro RE.Towards a definite mouse model of NAFLD..J Hepatol2018;69:272-4

[66] Fujii M,Wakamatsu K,Kawauchi Y.A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma..Med Mol Morphol2013;46:141-52

[67] Febbraio MA,Shalapour S,Watt MJ.Preclinical models for studying NASH-driven HCC: how useful are they?.Cell Metab2019;29:18-26 PMCID:PMC6326872

[68] Takakura K,Fujii M,Shibazaki Y.Characterization of non-alcoholic steatohepatitis-derived hepatocellular carcinoma as a human stratification model in mice..Anticancer Res2014;34:4849-55

[69] Arfianti E,Lee S,Haigh G.Obesity and diabetes accelerate hepatocarcinogenesis via hepatocyte proliferation independent of NF-κB or Akt/mTORC1..J Clin Transl Res2016;2:26-37 PMCID:PMC6410642

[70] Teufel A,Erhart W,Wang XY.Comparison of gene expression patterns between mouse models of nonalcoholic fatty liver disease and liver tissues from patients..Gastroenterology2016;151:513-25

[71] Nakagawa H,Taniguchi K,Dhar D.ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development..Cancer Cell2014;26:331-43 PMCID:PMC4165611

[72] Shalapour S,Bastian IN,Burt AD.Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity..Nature2017;551:340-5 PMCID:PMC5884449

[73] Molina-Sánchez P.Iron overload and liver cancer..J Exp Med2019;216:723 PMCID:PMC6446872

[74] Zhou XY,Fleming RE,Waheed A.HFE gene knockout produces mouse model of hereditary hemochromatosis..Proc Natl Acad Sci U S A1998;95:2492-7 PMCID:PMC19387

[75] Pigeon C,Iancu TC,Lan JL.Carbonyl-ironsupplementationinduces hepatocyte nuclear changes in BALB/CJ male mice..J Hepatol1999;30:926-34

[76] Rothenberg BE.β2 knockout mice develop parenchymal iron overload: a putative role for class I genes of the major histocompatibility complex in ironmetabolism..Proc Natl Acad Sci U S A1996;93:1529-34 PMCID:PMC39974

[77] Muto Y,Ichihara K,Shimizu H.Disruption of FBXL5-mediated cellular iron homeostasis promotes liver carcinogenesis..J Exp Med2019;216:950-65 PMCID:PMC6446870

[78] Tripathi A,Brenner DA,Loomba R.The gut-liver axis and the intersection with the microbiome..Nat Rev Gastroenterol Hepatol2018;15:397-411 PMCID:PMC6319369

[79] Yu LX.The gut microbiome and liver cancer: mechanisms and clinical translation..Nat Rev Gastroenterol Hepatol2017;14:527-39 PMCID:PMC6467288

[80] Yoshimoto S,Atarashi K,Sato S.Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome..Nature2013;499:97-101

[81] Achiwa K,Ishizu Y,Honda T.DSS colitis promotes tumorigenesis and fibrogenesis in a choline-deficient high-fat diet-induced NASH mouse model..Biochem Biophys Res Commun2016;470:15-21

[82] Dapito DH,Gwak GY,Jang MK.Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4..Cancer Cell2012;21:504-16 PMCID:PMC3332000

[83] Poutahidis T,Levkovich T,Mirabal S.Dietary microbes modulate transgenerational cancer risk..Cancer Res2015;75:1197-204 PMCID:PMC4383701

[84] Llopis M,Wrzosek L,Bruneau A.Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease..Gut2016;65:830-9

[85] Xu W,Chen M,McCaughan GW.Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives..Ther Adv Med Oncol2019;11:1758835919862692 PMCID:PMC6651675